Coherus Oncology, Inc.
Coherus Oncology, Inc. (Nasdaq: CHRS) is an oncology company that develops and commercializes immuno-oncology medicines. Its marketed product, LOQTORZI (toripalimab), is an anti-PD-1 antibody approved in the United States for adults with nasopharyngeal carcinoma, both with chemotherapy as a first-line treatment and as… From the company’s description.
Over the twelve months to Jun 30, 2026, Coherus Oncology, Inc. reported revenue of $50.94M and a net loss of $132.13M. Its operating margin was −311.6%, and operations used $186.03M in cash. In fiscal 2025, it reported revenue of $42.17M and net income of $168.02M.
Dotted labels explain each measure. is shown separately from the annual figures.
What Coherus Oncology, Inc. does
In the company’s own words
Coherus Oncology, Inc. (Nasdaq: CHRS) is an oncology company that develops and commercializes immuno-oncology medicines. Its marketed product, LOQTORZI (toripalimab), is an anti-PD-1 antibody approved in the United States for adults with nasopharyngeal carcinoma, both with chemotherapy as a first-line treatment and as monotherapy after platinum-containing chemotherapy; the company sells it in the United States and Puerto Rico. Coherus is also developing casdozokitug, an investigational antibody targeting IL-27, and tagmokitug, an investigational antibody targeting CCR8, for potential use in cancers including liver, head and neck, gastrointestinal and colorectal cancers. The company holds global development and commercialization rights to these candidates and plans to study them in combinations with LOQTORZI and other treatments. Its business is focused exclusively on proprietary immuno-oncology medicines following divestitures of its biosimilar businesses and its 2023 acquisition of Surface Oncology, which brought pipeline assets including tagmokitug. Coherus reported 2025 revenue of $[not provided in supplied text]. Its website is not stated in the supplied text.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1512762
- SIC
- 2836
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Coherus Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Coherus Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Coherus Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Coherus Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Coherus Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”